Serrapeptase: Systemic Enzyme Therapy & What the Research Says

Serrapeptase (serratiopeptidase) is a proteolytic enzyme originally isolated from the bacterium Serratia marcescens found in the intestine of silkworms. The silkworm uses it to dissolve its cocoon — and this ability to break down non-living protein tissue is the basis for its proposed therapeutic applications in humans.

Proposed Mechanisms

Serrapeptase is thought to reduce inflammation by breaking down fibrin and other dead or damaged tissue, thinning mucus secretions, and modulating inflammatory mediators. It's marketed for sinusitis, post-surgical swelling, carpal tunnel syndrome, and various inflammatory conditions.

What the Evidence Actually Shows

The evidence for serrapeptase is mixed. Some small studies (particularly from Japan and Italy) have shown benefits for post-operative swelling and sinusitis, but many of these studies have methodological limitations. Larger, higher-quality trials are needed. It's more popular in Europe and Asia than in the US, where it's sold as a dietary supplement.

Serrapeptase and nattokinase are the two most commonly discussed systemic enzymes. While both are proteolytic, nattokinase has more specific fibrinolytic (clot-dissolving) research behind it.